We reviewed the clinical and demographic characteristics and outcomes for 13 immunocompromised patients with herpes simplex virus (HSV)-induced meningitis. Eleven patients were receiving chemotherapy for leukemia or lymphoma, and 10 had acquired immunodeficiency syndrome. Patients presented with acute febrile meningitis. The median white blood cell count at the onset of symptoms was 400 cells/mm 3 . Examination of cerebrospinal fluid (CSF) specimens showed lymphocytic meningitis, but activated lymphocytes and low glucose levels were both noted in 7 patients. HSV DNA was detected in all CSF specimens, and HSV type 2 was identified in 7. Eight patients had suspected HSV-associated mucocutaneous lesions at the time of meningitis onset. Six patients had initial radiculalgia, with sphincter involvement in 2. Eleven patients received intravenous antiviral therapy, but treatment was delayed for 6 patients. Two of the 6 patients for whom treatment was delayed developed encephalitis and died, whereas 2 others experienced persistent neurological symptoms. HSV-2 can cause severe meningitis in immunocompromised patients. Early recognition and treatment might improve the outcome of such infections.
diagnostic purposes, were prospectively tested by PCR for detection of HSV DNA.
Clinical and radiological data for patients with positive results of CSF PCR were reviewed by 2 investigators who classified the patients as having meningitis or encephalitis. The diagnoses of meningitis and encephalitis were made on the basis of criteria reported elsewhere [6, 7, 11] . Patients were considered to have herpetic encephalitis if HSV was detected in CSF by PCR, in association with at least 1 of the following conditions: (1) an alteration in mental status, (2) a focal neurological symptom, (3) any abnormal result of electroencephalography, and (4) a necrotic lesion on a CT scan or MRI. Patients were considered to have HSV-induced meningitis if CSF PCR was positive for HSV DNA, in association with at least 1 of the following conditions: (1) any symptoms associated with meningitis (e.g., headache, vomiting, nausea, or neck stiffness), without alteration of mental status and without focal CNS symptoms; (2) normal brain CT scan or MRI findings, if performed; (3) abnormal results of cytological or biochemical testing of CSF, with negative results of cultures for bacteria, mycobacteria, and fungi; and 4) no evidence of any other virus in the CSF, including varicella-zoster virus (VZV), cytomegalovirus (CMV), human herpes virus type 6 (HHV-6), and Epstein-Barr virus (EBV), as assayed by PCR. Data collected from the medical charts included demographic characteristics, past medical history, and neurological and general signs and symptoms at hospital admission. The following biological data were also obtained: results of CSF hematological and biochemical tests, serum biochemical tests, and whole blood hematological tests.
Detection of HSV DNA in CSF. Detection of HSV DNA in CSF specimens was performed by PCR analysis. PCR was assayed using the Herpes Consensus Generic and herpes identification Hybridowell tests (Argène-Biosoft), in accordance with the manufacturer's instructions [12] . If brief, by means of the Herpes Consensus Generic kit, amplification was performed using primers located in the relatively conserved region of the DNA polymerase genes of 6 Herpesviridae species (HSV-1, HSV-2, CMV, VZV, EBV, and HHV-6). Amplified products were detected by hybridization with biotinyled probes. After the subsequent addition of a streptavidine-peroxydase conjugate and a tetramethylbenzidene component, optic density was measured at 450 nm. Samples in which the generic probe detected a positive signal were subsequently identified via hybridization with 6 single-specific probes using the herpes identification Hybridowell kit.
CSF samples obtained from 1994 through 1999 were initially tested with a global (i.e., not type-specific) HSV PCR assay [4] . Amplified products were detected using microplate hybridization with a biotinyled probe (Gen-Eti-K DEIA; DiaSorin), in accordance with the manufacturer's instructions. CSF samples that were initially positive for HSV DNA and stored at Ϫ80ЊC were retested in our study using the Herpes Consensus Generic assay.
Detection of anti-HSV antibodies in serum. The synthesis of specific antibodies to HSV-1 and HSV-2 in serum was assessed by an immunoenzymatic assay (HSV-1 and HSV-2 recombinant IgG ELIT; Eurobio).
Isolation of HSV-1 and HSV-2. HSV isolation was performed using tissue culture. Secretions obtained from peripheral blisters were inoculated in MRC5 diploid cells and incubated at 37ЊC. After a 48-h incubation period, HSV infection was determined by staining with monoclonal antibodies against HSV-1 and HSV-2 (CHA437; Argène-Biosoft). When the test results were positive, the HSV type was determined using immunofluorescence with type-specific monoclonal antibodies (Microtrak; Dade Behring).
RESULTS

Patients with HSV-induced meningitis.
Of the 919 CSF samples obtained during the study period and tested for HSV DNA using PCR, 30 (3.3%) tested positive for HSV DNA. Three samples were obtained from patients admitted to other hospitals, and their medical records were not available. Two patients most likely had false-positive PCR results. Among the remaining 25 patients, 7 (28%) had encephalitis, with alteration of their mental status and focal neurological symptoms.
Eighteen patients had HSV-induced meningitis, on the basis of our criteria. The prevalence of HSV-induced meningitis was, therefore, 2% in our study. Two patients had herpetic meningitis concomitant with a primary genital infection, and 2 had a typical case of recurrent benign lymphocytic meningitis. One patient was lost to follow-up 3 days after diagnosis.
Of interest, 13 patients were severely immunocompromised at the time of diagnosis; these patients are the focus of this study. Ten patients were infected with HIV and had AIDS diagnosed a median of 5.5 years (range, 1-13 years) before the episode of meningitis. The median CD4 + cell count for these 10 patients was 103 cells/mm 3 (range, 4-303 cells/mm 3 ), and the median plasma HIV-1 RNA load was 11,500 copies/mL. All but 1 of these HIV-infected patients were treated with antiretroviral therapy when they had meningitis, and 8 also received chemotherapy for the treatment of non-Hodgkin lymphoma. The 3 other immunocompromised patients had an acute transformation of a case of chronic myelogenous leukemia ( ) or lymphoma ( ) and were also receiving n p 1 n p 2 chemotherapy. Table 1 summarizes the demographic and clinical characteristics of these 13 patients and their symptoms at the onset of meningitis.
Clinical presentation involved acute meningeal syndrome, with headache (100% of patients), asthenia (100%), fever (92%), and neck stiffness (77%). None of the patients presented with seizures, altered mental status, or focal central neurological deficit at admission. Six had initial radiculalgia, with sphincter involvement in 2 cases. The median duration of clinical symptoms before CSF samples were obtained was 8 days (range, 1-36 days). Eight patients (62%) presented with cutaneous or mucosal lesions suggestive of HSV infection before (median, 4 days) or concomitant with meningitis. All patients underwent brain CT and/or MRI, the findings of which were always normal. Funduscopic examination was performed for 11 patients, and findings were normal. Of note, before CSF was obtained, all 13 immunocompromised patients had neutropenia (defined as a WBC count of !1000 cells/mm 3 ), and 12 had lymphopenia at the onset of meningeal symptoms. The median WBC count at the onset of clinical symptoms was 400 cells/mm 3 (range, 100-1000 cells/ mm 3 ). Neutropenia was due to chemotherapy in 11 patients and due to high-dose cotrimoxazole therapy for Pneumocystis carinii pneumonia and maintenance ganciclovir therapy for CMV retinitis in 2 of the HIV-infected patients. Findings from other blood tests were unremarkable. The median interval between the initiation of chemotherapy and the onset of meningeal symptoms was 10 days. It is interesting that none of these patients were receiving anti-HSV prophylaxis at the onset of symptoms, and only 1 was receiving low doses of ganciclovir.
CSF findings. The CSF cytological findings and protein and glucose concentrations are summarized in table 2. The WBC count was !400 cells/mm 3 in all patients, with a median WBC count of 74 cells/mm 3 and an elevated protein concentration of 0.72 g/L. Mononuclear cells were predominant in all samples tested. In 7 (54%) of 13 patients, there was a low CSF glucose concentration (i.e., !50% of the plasma concentration). Mononuclear cells were described as activated or atypical in 7 patients, with great polymorphism in size and large cytoplasmic granulations, and were suspected to be associated with lymphoma with meningeal involvement. Cultures for bacteria, mycobacteria, and fungi remained sterile for all patients. No concomitant viral infection in the CSF was detected by PCR.
Virological results. By means of PCR, HSV DNA was detected in all CSF samples and HSV-2 was identified in 7 of 7 samples. HSV-1 was never identified in CSF. HSV-2 was isolated from specimens of concomitant cutaneous lesions obtained from 5 patients, 2 of whom had an untyped HSV meningeal infection. One patient with untyped HSV meningitis had isolated serum antibodies against HSV-2. In 3 cases, patients had both anti-HSV-1 and anti-HSV-2 antibodies detected in serum, and the type of HSV-induced meningitis could not be determined. Overall, HSV-2 was likely to be responsible for at least 10 (77%) of the 13 cases of meningitis. All but 1 patient (for whom no serum sample was available for testing) had evidence of a positive HSV-2 serology at or before the onset of meningitis.
Clinical course and outcome. Patients were observed for a median duration of 90 days (range, 8-1800 days) after the episode of meningitis. Two of the patients did not receive any treatment, and 11 patients (85%) received antiviral therapy with intravenous acyclovir (10-15 mg/kg per day t.i.d.) or foscavir (1 patient) for at least 3 days. The median duration of treatment was 13.5 days (range, 3-35 days). A favorable outcome was noted in 7 patients, 5 of whom received antiviral therapy. The median time between symptom onset and initiation of therapy was 2 days for these patients.
Patients 7 and 5 (table 3) , for whom the initiation of antiviral therapy was delayed by 17 and 44 days, respectively, developed severe neuropathy with pain in both legs, associated with paraparesia, urinary retention, and anal incontinence. The first patient developed meningitis during treatment for lymphoma. Because of the presence of activated lymphocytes in the CSF, a diagnosis of lymphomatous meningitis was suspected. He received intravenous and intrathecal corticosteroid therapy. Intravenous acyclovir was started 17 days after the onset of symptoms. Despite this treatment, the symptoms persisted as definitive sequelae. For the second patient, the delay from the onset of symptoms to the treatment of HSV-induced meningitis was 44 days. Sixty days after the initiation of antiviral therapy, however, the symptoms eventually improved. Four immunocompromised patients died after the episode of meningitis. Two deaths were associated with the underlying hematological malignancy, but the other 2 were likely due to HSV-induced encephalitis. These 2 patients developed encephalitis 17 and 50 days after the onset of meningitis. The first patient was infected with HIV and had a low CD4 + cell count. She initially received no treatment for HSV-induced meningitis. Forty-five days later, however, she developed an altered mental status and received anti-HSV therapy. A second lumbar puncture confirmed the presence of HSV-2 in CSF. She died 4 days later from acute HSV-2-associated encephalitis, with temporal necrosis revealed on MRI. The second patient had lymphoma without HIV infection. Because of the low glucose concentration and the presence of activated lymphocytes in the CSF, a meningeal extension of the lymphoma was suspected. The patient subsequently received intravenous and intrathecal chemotherapy and developed encephalitis. An MRI of the brain showed bilateral temporal necrosis. He died 3 days later, despite the initiation of intravenous acyclovir therapy.
It is interesting to note that 6 patients received prophylactic anti-HSV therapy with valacyclovir ( ), oral acyclovir n p 3 ( ), and intravenous acyclovir ( ) during 13 following n p 2 n p 1 courses of chemotherapy for their malignancies, and none experienced a relapse of HSV-induced meningitis.
DISCUSSION
During the 7-year period of this study, we identified 18 cases of HSV-induced meningitis in our institution, on the basis of detection of HSV DNA in CSF by PCR. The prevalence of HSV-induced meningitis was 2% and was comparable to that of previous reports, in which the prevalence ranged from 0.5% to 3.9% [6, [13] [14] [15] .
We focused our attention on the 13 severely immunocompromised patients who presented with HSV-induced menin- gitis. The majority (11 of 13) of these patients were receiving chemotherapy for the treatment of lymphoma or leukemia. Also, 10 patients had AIDS, of whom 8 had HIV-associated lymphoma. In these patients, the causative process responsible for meningitis was likely a viral reactivation, because all but 1 patient had antibodies against HSV-2 detected in serum at the onset of symptoms. Furthermore, 8 patients had a history of previous herpes genitalis. The absence of previous HSV recurrences should not rule out reactivation however, because only 25% of patients with anti-HSV antibodies usually report having a prior history of HSV infection [16, 17] . HSV-2 was the likely cause of meningitis in our patients, and cases of HSV-induced meningitis have indeed been reported as being mainly due to HSV-2 [18] . HSV-2 reactivation in our patients may have been triggered by lymphopenia and/ or neutropenia. Indeed, HSV-1 recurrences during neutropenia have been well described and cause mucitis in patients with cancer [19] . Also, relationships between immunity and HSV infections have been studied in various animals with corneal (for HSV-1) and vaginal (for HSV-2) infections. In these animals, the infection caused fatal encephalitis in animals that were not previously immunized [20] [21] [22] . When animals were previously immunized with a less neuroinvasive strain, they were capable-following rechallenge with a wild strain-to mount a rapid cellular immune response, allowing for a rapid viral clearance and prevention of CNS involvement [20] [21] [22] . In such immunized animals, however, drug-induced neutropenia led to a less efficient and delayed viral clearance and to virus loads that were 100-1000-fold more than those seen in nonneutropenic animals [20, 22] . Similarly, low CD4 + T lymphocyte counts before reinfection led to the same consequences, with high local virus load [23] . On the basis of these data [20] [21] [22] [23] , we think that HSV-induced meningitis in our immunocompromised patients was triggered both by neutropenia and CD4 + T cell deficiency. Neutropenia and low CD4 + T cell counts could also explain the high rate (62%) of HSV cutaneous recurrences noted in our study. HSV viremia, however, was unlikely, because none of the patients had evidence of lung, liver, or gut involvement during the course of meningitis [24] .
The clinical symptoms, biological parameters, and CSF characteristics for our patients were similar to those reported in the literature for immunocompetent patients. Of interest, we noted hypoglycorachia in 7 of our patients, a feature that is rarely reported as being associated with the course of this infection [3, 6] . Also, the activated aspect of lymphocytes in the CSF in 7 patients, who had hematological malignancies, delayed the diagnosis of HSV-induced meningitis. Indeed, some of these patients received a misdiagnosis of lymphomatous meningitis and received corticosteroid and/or chemotherapy that most likely altered the course of HSV-induced meningitis. These data underscore the need for a systematic screening for HSV DNA in CSF in such clinical situations.
Compared with HSV-1-induced encephalitis, the outcome of HSV-induced meningitis has been reported to be spontaneously favorable without the use of antiviral therapy in otherwise healthy hosts [6] . However, in immunocompromised patients, neurological complications were occasionally described. Myelitis was reported in 5 patients with cancer or diabetes [25] . HSV-associated myelitis has also been described in HIV-infected patients with CD4
+ cell counts of !50 cells/ mm 3 , leading to encephalitis in some instances [25] [26] [27] [28] . The outcome in these patients was usually unfavorable, despite the use of antiviral therapy. However, it was difficult to sort out the direct role of HSV infection in these patients, because they also had CSF CMV coinfection [26] . Four of our patients also developed severe complications, leading to encephalitis and death in 2 cases. The severity of clinical symptoms in our study could also be associated with a low CD4 + T cell count. Indeed, the 2 patients who developed encephalitis had very low CD4 + T cell counts (22 and 4 cells/mm 3 ).
The benefit of using antiviral therapy to treat HSV-induced meningitis is unclear [29] . Our data may suggest that anti-HSV therapy should be started as soon as possible for immunocompromised patients with HSV-induced meningitis. Indeed, a delay in the administration of antiviral therapy seems to have been associated with severe complications in our patients. The dogma of early diagnostic and treatment developed for antiherpetic treatment in HSV-induced encephalitis might therefore be applicable to herpetic meningitis in immunocompromised patients. In addition, for such patients, the use of acyclovir prophylaxis to prevent new episodes of HSV-induced meningitis during further episodes of neutropenia should be considered. Indeed, no patient (except 1 who received low-dose ganciclovir) was receiving anti-HSV prophylaxis at the time of meningitis onset, and 6 of our patients who subsequently received anti-HSV prophylaxis did not experience any recurrence of HSV-induced meningitis, despite having undergone 13 subsequent chemotherapy courses with neutropenia. However, caution should be taken in this patients' population, because of the risk of selection of resistance [27] .
In conclusion, we believe that HSV-induced meningitis should be considered as a cause of lymphocytic meningitis in immunocompromised patients, especially when neutropenia and/or lymphopenia are present and when concomitant cutaneous recurrences are observed. Results of PCR for detection of HSV DNA in CSF should be obtained as soon as possible. We suggest that immunocompromised patients should receive immediate antiviral therapy and that antiviral prophylaxis should be considered for such patients if they are at risk for recurrence of neutropenia.
